{
    "clinical_study": {
        "@rank": "10059", 
        "acronym": "CRVO", 
        "arm_group": {
            "arm_group_label": "Intravitreal injection of Ranibizumab", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Recent studies have shown that intravitreal injection of anti-VEGF agent, Lucentis\n      (Ranibizumab) is effective for macular edema associated with central retinal vein occlusion\n      (CRVO). However, there is little information on whether there are any predictive factors of\n      treatment outcome after this treatment. We plan to perform comprehensive functional and\n      imaging tests to determine significant predictive factors."
        }, 
        "brief_title": "Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO", 
        "condition": "Central Retinal Vein Occlusion", 
        "condition_browse": {
            "mesh_term": [
                "Macular Edema", 
                "Retinal Vein Occlusion"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of the present study is to investigate predictive factors of treatment outcome\n      after intravitreal injection of Lucentis (Ranibizumab) in eyes with macular edema associated\n      with central retinal vein occlusion (CRVO) using various comprehensive clinical tests\n      including visual filed, spectral-domain optical coherence tomography (SD-OCT), ultra\n      wide-field fluorescein angiography, new flicker electroretinogram (ERG) using skin\n      electrodes. Corrected visual acuity, visual filed, spectral-domain optical coherence\n      tomography (SD-OCT), ultra wide-field fluorescein angiography, and new flicker\n      electroretinogram (ERG) using skin electrodes are performed before and 3, 6, 9, 12 months\n      after the treatment.  Predictive factors of treatment outcome are statistically analyzed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Macular edema associated with central retinal vein occlusion\n\n          -  Best corrected visual acuity  < 20/30\n\n          -  Central macular thickness > 300\n\n          -  Period from symptom onset to treatment < 12 months\n\n        Exclusion Criteria:\n\n          -  Any past history of treatment for macular edema (e.g. anti-VEGF injection, steroid,\n             vitrectomy)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02091505", 
            "org_study_id": "MKONDO-CRVO"
        }, 
        "intervention": {
            "arm_group_label": "Intravitreal injection of Ranibizumab", 
            "intervention_name": "Ranibizumab", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 17, 2014", 
        "link": {
            "description": "Department of Ophthalmology, Mie University Graduate School of Medicine", 
            "url": "http://www.medic.mie-u.ac.jp/ophthalmology/"
        }, 
        "location": {
            "contact": {
                "email": "mineo@clin.medic.mie-u.ac.jp", 
                "last_name": "Mineo Kondo, MD. PhD.", 
                "phone": "+81-59-231-5027"
            }, 
            "facility": {
                "address": {
                    "city": "Tsu", 
                    "country": "Japan", 
                    "state": "Aichi", 
                    "zip": "514-8507"
                }, 
                "name": "Mie University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Predictive Factors of Treatment Outcome After Intravitreal Injection of Lucentis (Ranibizumab) in Eyes With Macular Edema Associated With Central Retinal Vein Occlusion (CRVO)", 
        "overall_contact": {
            "email": "mineo@clin.medic.mie-u.ac.jp", 
            "last_name": "Mineo Kondo, MD, PhD", 
            "phone": "+81-59-231-5027"
        }, 
        "overall_official": {
            "affiliation": "Mie University Hospital", 
            "last_name": "Mineo Kondo, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Best-corrected visual acuity", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "reference": [
            {
                "PMID": "20381871", 
                "citation": "Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY; CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010 Jun;117(6):1124-1133.e1. doi: 10.1016/j.ophtha.2010.02.022. Epub 2010 Apr 9."
            }, 
            {
                "PMID": "23415775", 
                "citation": "Bhisitkul RB, Campochiaro PA, Shapiro H, Rubio RG. Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology. 2013 May;120(5):1057-63. doi: 10.1016/j.ophtha.2012.11.011. Epub 2013 Feb 14."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02091505"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mie University", 
            "investigator_full_name": "Mineo Kondo", 
            "investigator_title": "MD. PhD.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mie University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mie University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}